Multiple duodenal ulcer: natural history and pathophysiology

W M HUI AND S K LAM

From the Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong

SUMMARY It has not been established whether multiple duodenal ulcer is associated with a different natural history, pathophysiology, and therapeutic response than a single duodenal ulcer. A consecutive series of 96 patients with two or more duodenal ulcers at endoscopy, representing 9.6% of the total number of new patients with duodenal ulcer seen during the period 1980–1985, were compared with a random series of 200 patients with single duodenal ulcer seen in the middle years of this period. Multiple duodenal ulcer was associated with higher (p<0.02) male to female ratio, more (p<0.05) late onset patients (those with ulcer symptoms starting after age 30 years, more (p<0.05) chronic cigarette smokers, and more frequent (p<0.05) moderate to severe deformity of the duodenal bulb. More (p<0.05) patients with multiple duodenal ulcer had abnormally low D50 derived from pentagastrin dose response tests, indicating that they were more sensitive to gastrin stimulation. Furthermore, their mean fasting and meal stimulated serum gastrin concentrations were significantly higher than those of patients with single ulcer (p<0.005), or of controls (p<0.05). Compared with single duodenal ulcer, multiple duodenal ulcer had significantly lower placebo healing rate, and required a higher dose of misoprostol (1200 vs 800 µg/day) to achieve a similar healing efficacy at four weeks. We conclude that multiple duodenal ulcer is associated with different clinical features, pathophysiology, and possibly therapeutic response from single duodenal ulcer, and appears to represent the more aggressive side of the ulcer spectrum.

The occurrence of more than one ulcer in the duodenum, usually in the form of kissing ulcers, has long been noted by radiologists, pathologists and surgeons. The frequency of multiple duodenal ulcer, its clinical characteristics, gastric acid and gastrin secretions, and natural history are, however, poorly understood. During the period 1980–1985, we had conducted five therapeutic trials on duodenal ulcer, in which the clinical, personal, physiological and endoscopic characteristics of all the patients were prospectively obtained. From a total of 998 new patients with duodenal ulcer seen during this period, we obtained a consecutive series of 96 patients with more than one duodenal ulcers. We have retrospectively compared these with a random series of 200 patients with single duodenal ulcer seen during the same period, and have observed that multiple duodenal ulcer is associated with distinct clinical features, gastrin levels, natural history, and therapeutic responses. This forms the basis of this report.

Methods

PATIENTS During the period 1980–1985, we recruited 96 consecutive patients with multiple (two or more) duodenal ulcers documented endoscopically. These patients along with others with single duodenal ulcer have been randomised into various therapeutic trials: (i) omeprazole vs placebo, n=120, (ii) cimetidine 200 mg ts 600 mg nocte vs 1 g/day, n=246, (iii) misoprostol 300 µg qid vs 200 µg qid vs placebo, n=229, (iv) cimetidine 1 g/day vs sucralfate 1 g qid, n=283, and (v) cimetidine 400 mg tds, 200 tds and
patients were defined as those having the age of onset of ulcer symptoms at age 30 years or below, and late onset as those whose symptoms started after age 30 years. Pain severity was scored as follows: nil=0, mild=1, off work or work interfering=2, severe, requiring immediate medical attention such as attending the casualty department=3. Familial dyspepsia was considered present when the patient indicated that ulcer dyspepsia, gastrointestinal bleeding, perforation, and/or gastric surgery had occurred in a first degree relative; this was scored as nil=0, one first degree relative=1, two=2, three or more or both parents=3. Stress at work was scored subjectively by patient as 0 to 3 and included work pressure and/or labour intensity of the job. Neurosis was scored according to the number of neurotic traits present with a maximum of three (insomnia, tension headache, palpitation, hand tremors, non-postural dizzyspells). Habitual cigarette smoking was scored as nil=0, <1/day=1, and >1/day=2. The majority of smokers had smoked continuously for >10 years, and all smokers had this habit for at least five years. Habitual alcohol consumption for at least five years was scored as nil=0, estimated alcohol <50 g/day=1, >50 g/day=2. Habitual analgesic consumption for at least one year was scored as nil=0, 1 dose/month=1, at least 1 dose/week=2; analgesics included aspirin, non-steroidal anti-inflammatory agents, and many forms of patent Chinese herbal medicine, the nature of which was mostly undefined.

**PHYSIOLOGICAL CHARACTERISTICS**

Basal acid output (BAO), maximal acid output (MAO), and dose of pentagastrin required for half MAO corrected for BAO (D50C) were measured on one morning from a pentagastrin dose response test. D50C was taken to represent the sensitivity of the parietal cells. Hypersecretor was defined as a patient having MAO/kg total body weight above 2 SD of the mean of normal as established previously in 100 normal Chinese subjects. Low D50C was defined as less than 50 ng/kg/h, as established previously in 38 normal controls.

Serum gastrin concentrations, fasting and in response to a standard breakfast consisting of 50 g protein, 40 g carbohydrate and 40 g fat in the form of milk drink (60 g Sustagen in 60 milk) and Chinese style rice congee (130 g minced beef in 240 ml plain congee with 5 ml cooking oil), were measured on another morning by radioimmunoassay. The integrated gastrin response after the standard meal of each subject was defined by computing the total area under the response curve from zero to 120 minutes. The tests were also carried out on 18 healthy volunteer controls. Based on the results of their basal and maximal acid output and serum gastrin concent-
trations, and using the diagnostic indices of Jensen et al., the possibility of Zollinger-Ellison syndrome has been excluded in most of the patients. In two suspicious patients gastrin response to secretin was further determined, and was negative for gastrinoma.

**Endoscopic Characteristics**

Endoscopy was carried out with a forward viewing panendoscope (Olympus GIF-P or XQ) within 72 hours after the start of treatment. The diameters and depths of the ulcer were estimated using the tips of the biopsy forceps. The endoscopic characteristics as listed in Table 2 were recorded. Ulcer site was described as anterior, posterior, floor, roof and apex (near the exit) of the duodenal bulb. The degree of surrounding inflammation was scored as gross hyperaemia, granularity, and/or oedema = 3, moderate = 2, mild = 1, absent = 0. The degree of deformity of the duodenal bulb was scored: actual narrowing of entrance or exit of the duodenal bulb by scar but still admitting the endoscope (external diameter = 9 mm) = 3, bilateral deformity = 2, unilateral deformity of bulb = 1, absent = 0. The findings at subsequent endoscopies were compared with those observed at the initial endoscopy, and the patient was classified immediately as healed (complete disappearance of ulcer with or without residual inflammation usually in the form of hyperaemia and granularity), or unhealed (persistence of ulcer, however small).

**Response to Placebo and Misoprostol**

*Placebo*

The healing response of multiple duodenal ulcer to omeprazole placebo (one tablet at bedtime, n=13) and misoprostol placebo (two tablets half hour before breakfast, lunch and supper, and at bedtime, n=6) in two clinical trials were pooled together for analysis. The two trials were identical in design except for the medications, and both had endoscopic assessment at 2 week intervals for at least 4 weeks, and, if the ulcer remained unhealed, up to 12 weeks.

*Misoprostol*

The response of multiple duodenal ulcer to different doses of therapeutic agent was studied by analysis of the results of a randomised therapeutic trial comparing misoprostol 200 µg qid, misoprostol 300 µg qid, and placebo in the healing of duodenal ulcer. In this study, antacid tablets (Gelusil, containing magnesium trisilicate 500 mg and dried aluminium hydroxide gel 250 mg with a neutralising capacity of 6 mmol/l HCl) was allowed for pain relief. Patients

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Physiological characteristics</th>
<th>Multiple DU</th>
<th>Single DU</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAO</td>
<td>mmol/h</td>
<td>3.2±0.3-2</td>
<td>3.0±0.18</td>
<td>0.45</td>
</tr>
<tr>
<td>MAO</td>
<td>mmol/h</td>
<td>28.5±1.4</td>
<td>27.2±0.72</td>
<td>0.75</td>
</tr>
<tr>
<td>MAO/kkg</td>
<td>mmol/h/kkg</td>
<td>0.50±0.03</td>
<td>0.49±0.01</td>
<td>0.83</td>
</tr>
<tr>
<td>Hypersecretors</td>
<td>%</td>
<td>47±8</td>
<td>48±8</td>
<td>0.90</td>
</tr>
<tr>
<td>D90c</td>
<td>ng/kg.h</td>
<td>154±6.20</td>
<td>123±5.10</td>
<td>0.40</td>
</tr>
<tr>
<td>Low D90c</td>
<td>%</td>
<td>42±2</td>
<td>28±8</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Fasting gastrin</td>
<td>mmol/l</td>
<td>5±1±0.4</td>
<td>3±1±0.2</td>
<td>&lt;0.0002</td>
</tr>
<tr>
<td>Σ gastrin</td>
<td>mmol/min/l</td>
<td>10±5±0.1</td>
<td>7±3±0.4</td>
<td>&lt;0.005</td>
</tr>
</tbody>
</table>

were endoscoped at two week intervals until the ulcer healed for at least four weeks and up to a maximum of 12 weeks. After the ulcer had healed, patients were interviewed at two month and endoscoped at four month intervals. They were to report to the ulcer clinic immediately whenever their symptoms of ulcer recurred, and endoscopy would then be carried out. The details of the trial were reported previously.

**Statistical Analysis**

Student's t test, chi test for parametric data, Mann-Whitney test for non-parametric data, and life table analysis were used as appropriate. Values were expressed as mean±SE, and p values of less than 0.05 (two-sided) were considered significant.

**Results**

During the period 1980-1985, we recruited 998 new patients with duodenal ulcer into five therapeutic trials, of which 96 patients (9.6%) had multiple duodenal ulcer.

**Clinical and Personal Characteristics**

The characteristics of the 96 patients with multiple and the 200 patients with single duodenal ulcer are listed in Tables 1 and 2.

**Age and sex**

There were significantly (p<0.05) more male patients in the multiple ulcer group (84.4%, 81/96) than in the single ulcer group (72.0%, 148/200). The mean age of the multiple-ulcer (38.2±1.5 yr) group and single ulcer (37.7±0.95 yr) group were similar.

**Personal characteristics**

The mean scores for environmental stress and neurosis were practically identical in the multiple ulcer and single ulcer groups. There were significantly (p<0.05) more cigarette smokers in the multiple ulcer group (52.1%) than in the single ulcer group (38%). No significant differences were observed in their alcohol and analgesic consumptions.

**Endoscopy**

In the multi (bigger) ulcer group the ulcers were more frequently distributed in the body and antrum than in the single ulcer group (64±0.2). In contrast to the single ulcer group, all the multi ulcers were significantly different in distribution, and the ulcer area in the large ulcer was significantly less than that of the ulcers of the patients with severe defo
Multiple duodenal ulcer

**AGE OF ONSET AND GENETICS**
The mean age of onset of ulcer symptoms was 30.7±1.4 and 28.8±0.9 years respectively in the multiple ulcer and single ulcer groups. When the patients were classified into early and late onset—which is, age of <30 or >30 yr, significantly (p<0.05) more patients in the multiple ulcer group were of the late onset type when compared with the single ulcer group. A positive family history of dyspepsia occurred at similar frequencies in the two groups. Approximately half of the patients in both groups were of blood group O, and the proportions were significantly (p<0.0005) higher than that of the general population, in which blood group O constituted 40.4% (number of subjects studied=130000).15

**SYMPTOMS**
The mean duration of symptoms before presentation was 7.3±0.1 and 8.9±0.1 years respectively in the multiple ulcer and single ulcer groups, and were not statistically different. The latest period of remission, the current symptom period, and the character of the pain were not statistically different between the multiple ulcer and single ulcer groups. The duration of pain attack was longer in the multiple ulcer group (2.2±0.8 h) than in the single ulcer group (1.3±0.2 h), but the difference was not significant. The frequencies of melena and haematemesis were also not different between the two groups.

**Past history of ulcer disease**
Forty seven (49%) of the patients with multiple duodenal ulcer had their ulcers documented endoscopically for the first time in the present study. In the remaining patients, six (12.2%) had previous history of multiple duodenal ulcer documented endoscopically, and 43 (87.8%) were documented to have single ulcer.

**ENDOSCOPIC CHARACTERISTICS**
In the multiple ulcer group, 53.1% of the index (bigger) ulcers occurred anteriorly with a kissing ulcer at the posterior wall, and 17.7% of the index ulcers were situated on the floor, with an opposite ulcer at the roof. The mean diameter of the index ulcer was significantly (p<0.05) larger in the multiple ulcer group (7.2±0.3) than in the single ulcer group (6.4±0.2). The mean ulcer depths were not significantly different in the two groups. Likewise the mean score of inflammation in the two groups was not different. Deformity of the duodenal bulb was (p<0.005) more severe in the multiple ulcer than in the single ulcer group, 27.1% and 39.5% of the patients respectively having moderate to severe deformity.

**PHYSIOLOGICAL CHARACTERISTICS**

**Acid output**
The basal acid output (BAO), and the maximal acid output (MAO) of patients with multiple duodenal ulcer were respectively 3.26±0.32 and 28.2±1.4 mmol/l and were similar to those of the single ulcer group (Table 3).

**Sensitivity to pentagastrin**
Although D30, in the multiple ulcer and single ulcer groups were not statistically different, significantly (p<0.05) more patients with multiple duodenal ulcer (42.2%) had D30, that was below normal than those with single duodenal ulcer (29.8%), indicating that more patients with multiple duodenal ulcer might be hypersensitive to gastrin.

**Serum gastrin**
The mean fasting serum gastrin (pmol/l) in the multiple ulcer group (5.1±0.4) was significantly higher than that of the single ulcer group (3.8±0.2) (p<0.0002) and that of the normal subjects (2.8±0.3) (p<0.005).

At 30, 60, 120 minutes after the standard meal, the mean serum gastrin concentrations of patients with multiple ulcer were significantly higher than those of patients with single ulcer, the significant concentrations being p<0.001, <0.001, and <0.0005 respectively, as well as those of the normal controls, the significant concentrations being p<0.01, 0.05, 0.01 respectively (Fig. 1). The integrated two hour post-prandial serum gastrin was likewise significantly higher in the multiple ulcer group (10.5±1.0 nmol/min/l) than in the single ulcer group (7.3±0.4 nmol/min/l) (p<0.005) and in the controls (6.5±1.0 nmol/min/l) (p<0.05). The findings remained true when the male patients and controls alone were analysed (Fig. 2).

### Table 3 Endoscopic characteristics

<table>
<thead>
<tr>
<th>Individual value</th>
<th>Multiple DU</th>
<th>Single DU</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ulcer size mm</td>
<td>7±2±0.3</td>
<td>6±4±0.2</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Ulcer depth mm</td>
<td>1±8±0.1</td>
<td>1±7±0.1</td>
<td>0.28</td>
</tr>
<tr>
<td>Inflammation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1 %</td>
<td>11±5</td>
<td>11±0</td>
<td></td>
</tr>
<tr>
<td>1 %</td>
<td>47±9</td>
<td>49±5</td>
<td></td>
</tr>
<tr>
<td>2 %</td>
<td>30±2</td>
<td>36±0</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>3 %</td>
<td>10±4</td>
<td>3±5</td>
<td></td>
</tr>
<tr>
<td>Deformity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 0 %</td>
<td>34±4</td>
<td>46±5</td>
<td></td>
</tr>
<tr>
<td>1 %</td>
<td>38±5</td>
<td>33±5</td>
<td></td>
</tr>
<tr>
<td>2 %</td>
<td>20±8</td>
<td>18±0</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>3 %</td>
<td>6±3</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>
RESPONSE TO PLACEBO AND MISOPROSTOL

In the misoprostol study, a total of 229 patients including 21 with multiple and 208 with single duodenal ulcer were recruited into the study. Eight patients in the single ulcer and none in the multiple ulcer group dropped out.

Response to placebo

A total of 19 patients with multiple duodenal ulcer and 112 patients with single ulcer received placebo. They were patients who participated in two similarly designed, 12 week studies on omeprazole and misoprostol,* as described earlier.

The endoscopic healing rate at four weeks was significantly (p<0.05) lower in the multiple ulcer (5%) group than the single ulcer group (25%), but no significant differences in the healing rates were found at eight and 12 weeks between the multiple ulcer (42%, 47% respectively) and single ulcer groups (40%, 55% respectively), and in the overall comparison of the two ulcer groups over the 12 weeks of the study (p=0.19, life table analysis) (Fig. 3).

Response to misoprostol

The healing rates of the multiple ulcer and single ulcer groups were shown in Figure 4. Patients with multiple duodenal ulcer healed significantly slower than those with single duodenal ulcer when treated with misoprostol 200 μg qid (p<0.05 by life table analysis), but this disadvantage disappeared (p>0.5) when the patients were treated with the higher dose of misoprostol, 300 μg qid. At the end of four weeks, significantly (p<0.05) more patients with multiple duodenal ulcer on misoprostol 300 μg qid (87.5%) had their ulcers healed than those on misoprostol 200 μg qid (14%) (Fig. 4). Irrespective of the treatment received, patients with multiple duodenal ulcer consumed significantly more antacids than those with single duodenal ulcer all through the 12 week period of the study. For example, the mean number of antacids consumed by patients with single ulcer was 1 and placed in the multiple ulcer group dropped out.

Follow up

Sixty three patients commenced the treatment with misoprostol, 300 μg qid and were followed for 12 weeks. Ninety one patients had relapse of ulcer, 13% had no relapse, 12% had a recurrent ulcer, 13% were lost to follow up and 13% were on an alternative therapeutic regimen. Several complications of mesenteric panniculitis emerged from the clinical experience. The logical next step was to conduct a more controlled study in which the effectiveness and safety of mesenteric panniculitis could be assessed in a larger patient population.
Multiple duodenal ulcer

Patients with multiple duodenal ulcer have significantly more male preponderance, more cigarette smokers, and more late onset disease – that is, patients whose symptoms start after the age of 30 years. Duodenal ulcer has been shown to heal more spontaneously in men than in women. Cigarette smoking delays ulcer healing not only in patients treated with placebos but also in those treated with potent acid reducing agents such as H₂-receptor antagonists, as has recently been reviewed. Compared with early onset disease, late onset duodenal ulceration is known to be more often associated with virulent ulcers such as postbulbar ulcers and giant duodenal ulcers, and to be more often associated with perforation and pyloric stenosis. These observations suggest that multiple duodenal ulcer may be a more severe disease and may run a higher risk of complications than single duodenal ulcer.

This concept is further supported by the findings in this study that multiple duodenal ulcer is significantly bigger, associated with greater deformity of the duodenal bulb, and is significantly more difficult to heal than single duodenal ulcer, as evident by its lower placebo healing rate at four weeks, and the requirement of a higher dose of misoprostol than recommended. As the number of patients involved in the multiple duodenal ulcer group was small, however, further studies are required to confirm their apparent resistance to heal.

The pathophysiological basis for the aggressive nature of multiple duodenal ulcer is not clear. Both basal and maximal acid output are significantly

antacids consumed at the end of four weeks by patients taking misoprostol 300 μg qid, 200 μg qid and placebo were 1-1, 2-1, and 2-0 respectively in the single ulcer groups, and 3-8, 5-5, and 8-2 respectively in the multiple ulcer group. It should be noted that misoprostol 200 μg qid is the recommended dose for the treatment of duodenal ulcer as established by multiple therapeutic trials.

FOLLOW UP
Sixty three of the patients with multiple duodenal ulcer completed a follow up period of two years after initial healing of their ulcers by various therapeutic agents including H₂-receptor antagonists, misoprostol, sucralfate, and placebo. Forty eight (76-2%) had relapsed with a single ulcer, seven (11-1%) had relapsed with multiple ulcers, and eight (12-7%) had no relapse. Of the 200 patients with single duodenal ulcer, 134 had completed a follow up period of two years, and 107 (79-8%) had relapsed; none of the recurrent ulcers were multiple. Patients with multiple duodenal ulcer did not have an increased relapse rate (χ² = 1-16, p = 0.05).

Discussion
Several differences between patients with multiple duodenal ulcer and those with single duodenal ulcer emerge from this prospective study comparing their clinical and personal characteristics, gastric physiological measurements, natural history, and therapeutic response.
higher than normal, although these are not significantly different from those of patients with single duodenal ulcer. The fasting and meal-stimulated serum gastrin concentrations of patients with multiple duodenal ulcer are significantly higher than those of the single ulcer patients, however, as well as normal controls, and significantly more of them are abnormally sensitive to gastrin. These findings suggest that gastrin cell hyperfunction and gastrin hypersensitivity may be two basic physiological abnormalities in these individuals, and may be responsible for the multiplicity and aggressiveness of their ulcers. It is not known from this study whether these patients have antral G cell hyperplasia, a rare condition associated with gross hypergastrinaemia and acid hypersecretion. Gastrin cell hyperfunction in the form of postprandial but not fasting hypergastrinaemia has been described in patients with normal acid secretory capacity, and may occur in about one third of patients with duodenal ulcer. It is tempting to suggest that duodenal ulcer with postprandial hypergastrinaemia alone, which occurs commonly in about one third of the patients, multiple duodenal ulcer, which occurs in about 10% of patients with duodenal ulcer as shown in this study, and duodenal ulcer associated with antral G cell hyperplasia, which occurs rarely, fall in the same spectrum of duodenal ulcer having various degrees of gastrin cell abnormalities. Whether postprandial hypergastrinaemia has resulted in hypersecretion of meal-stimulated acid output is not known from this study, although this relationship has been shown in a previous report.

Treatment of duodenal ulcer associated with postprandial hypergastrinaemia does not differ from that of ordinary patients with duodenal ulcer, whereas treatment of patients with antral G cell hyperplasia may require surgical resection of the antrum. It is interesting that treatment of patients with multiple duodenal ulcer requires a higher dose of misoprostol than is generally recommended. Misoprostol is a synthetic prostaglandin E₁ derivative with potent antisecretory and cytoprotective properties, with a unique advantage of being able to nullify the adverse effects of cigarette smoking on duodenal ulcer healing, a habit which occurs more commonly in patients with multiple than with single duodenal ulcer as observed in this study.

Our follow-up study suggests that after the initial healing of the ulcers by various therapeutic agents, the majority of the patients with multiple duodenal ulcer tended to relapse with single ulcer rather than multiple ulcers, and only about 10% relapse with multiple ulcers. It is possible that the close follow-up of our patients with two monthly visits and four monthly endoscopies may have led to earlier detection of relapse, at a time when the ulcer was still single. It is also possible that the natural history of these patients is such that the ulcer may reappear as single or multiple ulcer depending on certain underlying, unknown factors. It is not known from this study whether the fasting and postprandial hypergastrinaemia, and the apparently slower response to treatment persist in these patients with relapse.

We conclude that multiple duodenal ulcer is associated with different pathophysiological, clinical features, natural history, and possibly, therapeutic responses from single duodenal ulcer.

This study was supported by the Peptic Ulcer Research Fund (311/041/0372) and University Grants (311/030/8009/31, 311/030/8010/12, 335/04/9006, 311/030/8010/69) of the University of Hong Kong.

The authors are grateful to M Chong, B Ng, J Wong, B Chik, and A Cheng for nursing assistance, and to GH Joe and P Yip for technical assistance.

References

5. Lam SK, Lai CL, M Ng, Fok KH, Hui WM. Duodenal ulcer healing by separate reduction of postprandial and nocturnal acid secretions have different pathophysiology. Gut 1985; 26: 1038–44.
12. Jensen RT, Gardner JD, Raufman JP, et al. Zollinger-
Multiple duodenal ulcer